Alice Gardham

Alice Gardham

Auto-generated profile, based on publicly available information

Alice Gardham

Department of Clinical Genetics Great Ormond Street Hospital for Children NHS Foundation Trust London UK

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
ADAnna Durkin
Anna Durkin
SAShadi Albaba
Shadi Albaba
AFAndrew E. Fry
Andrew E. Fry
JMJenny E. Morton
Jenny E. Morton
ADAndrew Douglas
Andrew Douglas
Meena BalasubramanianMeena Balasubramanian
Meena Balasubramanian
With advances in genetic testing and improved access to such advances, whole exome sequencing is becoming a first‐line investigation in clinical work‐up of children with developmental delay/intellectual disability (ID). As a result, the need to understand the importance of genetic variants and its effect on the clinical phenotype is increasing. Here, we report on the largest cohort of patients with HNRNPU variants. These 21 patients follow on from the previous study published by Yates et al. in 2017 from our group predominantly identified from the Deciphering Developmental Disorders study that reported seven patients with HNRNPU variants. All the probands reported here have a de novo loss‐of‐function variant. These probands have craniofacial dysmorphic features, in the majority including widely spaced teeth, microcephaly, high arched eyebrows, and palpebral fissure abnormalities. Many of the patients in the group also have moderate to severe ID and seizures that tend to start in early childhood. This series has allowed us to define a novel neurodevelopmental syndrome, with a likely mechanism of haploinsufficiency, and expand substantially on already published literature on HNRNPU‐related neurodevelopmental syndrome.

7 November 2017 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
DBD.R. Bertola
D.R. Bertola
GHGabriella Hsia
Gabriella Hsia
LAL. Alvizi
L. Alvizi
AGA. Gardham
A. Gardham
EWE.L. Wakeling
E.L. Wakeling
MPMaria Rita Passos-Bueno
Maria Rita Passos-Bueno

18 August 2023 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
FAFatima Alabdulrazzaq
Fatima Alabdulrazzaq
TATalal Alanzi
Talal Alanzi
HAHaya H. Al‐Balool
Haya H. Al‐Balool
AGAlice Gardham
Alice Gardham
EWEmma Wakeling
Emma Wakeling
DMDana Marafi
Dana Marafi
Background: Very long‐chain fatty acids (VLCFAs) composed of more than 20 carbon atoms are essential in the biosynthesis of cell membranes in the brain, skin, and retina. VLCFAs are elongated beyond 28 carbon atoms by ELOVL4 enzyme. Variants in ELOVL4 are associated with three Mendelian disorders: autosomal dominant (AD) Stargardt‐like macular dystrophy type 3, AD spinocerebellar ataxia, and autosomal recessive disorder congenital ichthyosis, spastic quadriplegia and impaired intellectual development (ISQMR). Only seven subjects from five unrelated families with ISQMR have been described, all of which have biallelic single‐nucleotide variants.Methods: We performed clinical exome sequencing on probands from four unrelated families with neuro‐ichthyosis.Results: We identified three novel homozygous ELOVL4 variants. Two of the families originated from the same Saudi tribe and had the exact homozygous exonic deletion in ELOVL4, while the third and fourth probands had two different novel homozygous missense variants. Seven out of the eight affected subjects had profound developmental delay, epilepsy, axial hypotonia, peripheral hypertonia, and ichthyosis. Delayed myelination and corpus callosum hypoplasia were seen in two of five subjects with brain magnetic rosonance imaging and cerebral atrophy in three.Conclusion: Our study expands the allelic spectrum of ELOVL4‐related ISQMR. The detection of the same exonic deletion in two unrelated Saudi family from same tribe suggests a tribal founder mutation.

18 June 2026 in Prenatal Diagnosis
Verified
Journal Article
Open access
AGA. Gibbs
A. Gibbs
RBR. Braham
R. Braham
VRV. Ramachandran
V. Ramachandran
RRR. Roberts
R. Roberts
CWC. Willison
C. Willison
NCN. J. Chandler
N. J. Chandler
Objective: Prenatal sequencing of fetuses with abnormalities detected on imaging is expanding globally. Debate continues over whether variants of uncertain significance (VUS) should be reported prenatally, with some recent national position statements opposing this. In England, VUS that fit the fetal phenotype and require little further evidence for upgrade are discussed at multidisciplinary team (MDT) meetings to determine whether to report. We review the VUS reported by one English laboratory that provides prenatal sequencing to half of England. Method: The laboratory's database was searched from 01/10/2020 to 30/04/2025 to ascertain all cases where a VUS was reported. Pregnancy outcomes were obtained from local clinical teams to determine whether the VUS status had been resolved. Results: VUS were reported in 41/881 fetuses sequenced. Follow‐up data were available for 38/41 cases, of which 23 were subsequently upgraded to likely pathogenic and 1 downgraded to likely benign. The most common reason for upgrade was new information from post‐mortem or postnatal review (17/23). Conclusion: There is clinical utility in reporting VUS from prenatal sequencing following MDT discussion. Although reporting VUS leaves parents with uncertainty, follow up (including post‐mortem when applicable) resolves this in over 50% of cases (79% of cases re‐examined pre‐ or postnatally).

19 May 2022 in medRxiv
Verified
Preprint
Open access
PDF file
LPLuke A. Perera
Luke A. Perera
AHAndrew T. Hattersley
Andrew T. Hattersley
HHHeather P. Harding
Heather P. Harding
MWMatthew N. Wakeling
Matthew N. Wakeling
SFSarah Flanagan
Sarah Flanagan
EFElisa De Franco
Elisa De Franco
Dysfunction of the endoplasmic reticulum (ER) in insulin-producing beta cells results in cell loss and diabetes mellitus. Here we report on 5 individuals from three different consanguineous families with infancy-onset diabetes mellitus and severe neurodevelopmental delay caused by a homozygous p.(Arg371Ser) mutation in FICD . The FICD gene encodes a bifunctional Fic domain-containing enzyme that regulates the ER Hsp70 chaperone, BiP, via catalysis of two antagonistic reactions: inhibitory AMPylation and stimulatory deAMPylation of BiP. Arg371 is a conserved residue in the Fic domain active site. The FICD R371S mutation partially compromises BiP AMPylation in vitro but eliminates all detectable deAMPylation activity. Overexpression of FICD R371S or knock-in of the mutation at the FICD locus of stressed CHO cells result in inappropriately elevated levels of AMPylated BiP. These findings, guided by human genetics, highlight the destructive consequences of de-regulated BiP AMPylation and raise the prospect of tuning FICD’s antagonistic activities towards therapeutic ends.